For example, failure of DAA combinations has been reported to occur more often in HCV patients with advanced cirrhosis, difficult to treat HCV genotypes, high HCV-RNA load, HIV coinfection and an unfavorable IL28B polymorphism5. This evidence concerns the gene IFNL3 and Cirrhosis.